Cargando…
ROBIS: A new tool to assess risk of bias in systematic reviews was developed
OBJECTIVE: To develop ROBIS, a new tool for assessing the risk of bias in systematic reviews (rather than in primary studies). STUDY DESIGN AND SETTING: We used four-stage approach to develop ROBIS: define the scope, review the evidence base, hold a face-to-face meeting, and refine the tool through...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687950/ https://www.ncbi.nlm.nih.gov/pubmed/26092286 http://dx.doi.org/10.1016/j.jclinepi.2015.06.005 |
_version_ | 1782406695466565632 |
---|---|
author | Whiting, Penny Savović, Jelena Higgins, Julian P.T. Caldwell, Deborah M. Reeves, Barnaby C. Shea, Beverley Davies, Philippa Kleijnen, Jos Churchill, Rachel |
author_facet | Whiting, Penny Savović, Jelena Higgins, Julian P.T. Caldwell, Deborah M. Reeves, Barnaby C. Shea, Beverley Davies, Philippa Kleijnen, Jos Churchill, Rachel |
author_sort | Whiting, Penny |
collection | PubMed |
description | OBJECTIVE: To develop ROBIS, a new tool for assessing the risk of bias in systematic reviews (rather than in primary studies). STUDY DESIGN AND SETTING: We used four-stage approach to develop ROBIS: define the scope, review the evidence base, hold a face-to-face meeting, and refine the tool through piloting. RESULTS: ROBIS is currently aimed at four broad categories of reviews mainly within health care settings: interventions, diagnosis, prognosis, and etiology. The target audience of ROBIS is primarily guideline developers, authors of overviews of systematic reviews (“reviews of reviews”), and review authors who might want to assess or avoid risk of bias in their reviews. The tool is completed in three phases: (1) assess relevance (optional), (2) identify concerns with the review process, and (3) judge risk of bias. Phase 2 covers four domains through which bias may be introduced into a systematic review: study eligibility criteria; identification and selection of studies; data collection and study appraisal; and synthesis and findings. Phase 3 assesses the overall risk of bias in the interpretation of review findings and whether this considered limitations identified in any of the phase 2 domains. Signaling questions are included to help judge concerns with the review process (phase 2) and the overall risk of bias in the review (phase 3); these questions flag aspects of review design related to the potential for bias and aim to help assessors judge risk of bias in the review process, results, and conclusions. CONCLUSIONS: ROBIS is the first rigorously developed tool designed specifically to assess the risk of bias in systematic reviews. |
format | Online Article Text |
id | pubmed-4687950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-46879502016-01-15 ROBIS: A new tool to assess risk of bias in systematic reviews was developed Whiting, Penny Savović, Jelena Higgins, Julian P.T. Caldwell, Deborah M. Reeves, Barnaby C. Shea, Beverley Davies, Philippa Kleijnen, Jos Churchill, Rachel J Clin Epidemiol Guidelines OBJECTIVE: To develop ROBIS, a new tool for assessing the risk of bias in systematic reviews (rather than in primary studies). STUDY DESIGN AND SETTING: We used four-stage approach to develop ROBIS: define the scope, review the evidence base, hold a face-to-face meeting, and refine the tool through piloting. RESULTS: ROBIS is currently aimed at four broad categories of reviews mainly within health care settings: interventions, diagnosis, prognosis, and etiology. The target audience of ROBIS is primarily guideline developers, authors of overviews of systematic reviews (“reviews of reviews”), and review authors who might want to assess or avoid risk of bias in their reviews. The tool is completed in three phases: (1) assess relevance (optional), (2) identify concerns with the review process, and (3) judge risk of bias. Phase 2 covers four domains through which bias may be introduced into a systematic review: study eligibility criteria; identification and selection of studies; data collection and study appraisal; and synthesis and findings. Phase 3 assesses the overall risk of bias in the interpretation of review findings and whether this considered limitations identified in any of the phase 2 domains. Signaling questions are included to help judge concerns with the review process (phase 2) and the overall risk of bias in the review (phase 3); these questions flag aspects of review design related to the potential for bias and aim to help assessors judge risk of bias in the review process, results, and conclusions. CONCLUSIONS: ROBIS is the first rigorously developed tool designed specifically to assess the risk of bias in systematic reviews. Elsevier 2016-01 /pmc/articles/PMC4687950/ /pubmed/26092286 http://dx.doi.org/10.1016/j.jclinepi.2015.06.005 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Guidelines Whiting, Penny Savović, Jelena Higgins, Julian P.T. Caldwell, Deborah M. Reeves, Barnaby C. Shea, Beverley Davies, Philippa Kleijnen, Jos Churchill, Rachel ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title | ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title_full | ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title_fullStr | ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title_full_unstemmed | ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title_short | ROBIS: A new tool to assess risk of bias in systematic reviews was developed |
title_sort | robis: a new tool to assess risk of bias in systematic reviews was developed |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687950/ https://www.ncbi.nlm.nih.gov/pubmed/26092286 http://dx.doi.org/10.1016/j.jclinepi.2015.06.005 |
work_keys_str_mv | AT whitingpenny robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT savovicjelena robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT higginsjulianpt robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT caldwelldeborahm robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT reevesbarnabyc robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT sheabeverley robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT daviesphilippa robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT kleijnenjos robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT churchillrachel robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped AT robisanewtooltoassessriskofbiasinsystematicreviewswasdeveloped |